You've just added:

Model Developed to Predict Efficacy Against SARS-CoV-2

Posted on June 07, 2022 in Center for COVID-19

Scholar in the News

Spring 2022

Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19

Entry of the SARS-CoV-2 coronavirus, which causes COVID-19, requires a host serine protease called TMPRSS2. Camostat mesylate, an orally available serine protease inhibitor, inhibits TMPRSS2, supporting clinical trials to investigate its use in COVID-19.

"The use of innovative modeling by Harrington gave us new insights into how to use Camostat clinically."

- Donald Stanski, MD, Harrington Discovery Institute

Advisor, Therapeutics Development Center

"Our team at Harrington Discovery Institute has stimulated deep, rigorous and invaluable thinking about the development of our drug."

- Joseph Vinetz, MD, FACP, FIDSA, FASTMH, BS

Read the full article in Microbiology Spectrum

About the Scholar

Joseph Vinetz

Infectious Disease, Virology

Joseph Vinetz, MD

Yale University
Harrington Award for Coronavirus

More about Joseph Vinetz

We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.